The development of CRC is closely associated with chronic inflammation and raised TNFα secretion [26] leading to therapeutic strategies aimed at minimizing chronic inflammation in these patients through TNFα inhibitors, ultimately reducing the risk of its CRC [27, 28]. Here, TNF is linked to colorectal carcinoma.